Type 2 diabetes hypoglycemic coma refers to a potential complication that may occur in patients with type 2 diabetes. Patients treated with insulin or long-acting sulfonylurea drugs have a high risk of hypoglycemia, especially the elderly and those with renal insufficiency, who are prone to hypoglycemia at night. Normally, the body maintains blood glucose levels within a relatively narrow range through complex, systematic, and precise regulatory mechanisms. Once an individual exceeds the utilization of glucose over the supply of glucose due to some reason, it breaks the stability of the body's blood glucose environment, and the plasma glucose concentration begins to decrease. This may include: an increase in insulin or insulin analogs in the blood; insufficient levels of glucocorticoids, glucagon, growth hormone, and adrenaline, etc., which increase blood glucose; severe insufficient intake and/or absorption of sugar; insufficient glycogen reserve and/or decomposition; excessive consumption of glucose by tissues and reduced gluconeogenesis, etc.
It is generally believed that the standard for hypoglycemia is: plasma glucose concentration less than 2.8 mmol/L (50 mg/dl). Hypoglycemia is the most common problem in diabetes treatment and should be avoided as much as possible. If hypoglycemia has no damaging effect on the human body, especially the brain, diabetes treatment would be extremely simple. Just use an adequate amount of insulin or sulfonylurea drugs to lower blood sugar, which can alleviate the symptoms caused by hyperglycemia, prevent acute and chronic complications such as retinopathy, renal and neurological lesions, and reduce the risk factors for atherosclerosis.